Drug intelligence / Profile preview

AVB-501

Development stage: Preclinical
Lead developer: Solid Biosciences
Modality: Gene Therapies

Overview

AVB-501 is an early-stage gene therapy candidate being developed by AviadoBio for the treatment of tauopathies, including Alzheimer's disease. The program is currently in the discovery phase and is designed to address neurodegeneration associated with the pathological accumulation of tau protein. While the specific molecular target and mechanism of action have not been publicly disclosed, the therapy likely leverages AviadoBio's proprietary delivery platforms, such as their intrathalamic delivery system or vMiX™ RNA silencing technology, to target the central nervous system and mitigate tau-mediated pathology.

Beyond the preview

Go deeper on AVB-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVB-501.

Explore the full profile